September 2025 in “International Journal of Pharmacy and Biomedical Engineering” Drug repurposing finds new uses for existing drugs, speeding up treatment availability and reducing costs.
42 citations
,
January 2018 in “Expert review of precision medicine and drug development” Drug repositioning is becoming more targeted and efficient with new technologies, offering personalized treatment options and growing interest in the field.
1 citations
,
July 2025 in “Functional Foods in Health and Disease” CL22209, an Asparagus racemosus extract, safely reduces perimenopausal symptoms and balances hormones.
3 citations
,
January 2016 in “Case reports in dermatological medicine” An 80-year-old man grew extra hair on his forearms after starting Alzheimer's medication rivastigmine.
July 2025 in “Scientific Reports” Pioglitazone, Trimipramine, and Dimetindene may be repurposed to treat psoriasis.
December 2023 in “Reactions weekly” December 2023 in “Reactions weekly” September 2013 in “Reactions weekly” June 2026 in “The Egyptian Journal of Neurology Psychiatry and Neurosurgery” Parkinson's disease (PD) is a debilitating neurodegenerative disorder with increasing prevalence, and current treatments only alleviate symptoms without stopping disease progression. Mesenchymal stem cells (MSCs) offer a promising approach for PD treatment due to their ability to differentiate into dopaminergic neurons and secrete neurotrophic factors, providing neuroprotective effects, promoting remyelination, reducing neural inflammation, and facilitating functional recovery. The therapeutic benefits of MSCs are mainly mediated through paracrine activity, particularly via extracellular vesicles (EVs) and exosomes, which can cross the blood-brain barrier and avoid ethical issues of cell-based therapies. Although the exact mechanisms are not fully understood, MSC-derived exosomes are believed to play a significant role in reparative effects, and bioengineering can enhance their drug delivery and targeting capabilities. This review discusses the potential of MSC and MSC-secretome/EV applications in PD treatment and suggests future research directions.
3 citations
,
March 2020 in “The Journal of Urology” Older patients sticking to their prostate medication saw lasting health benefits.
10 citations
,
November 2017 in “Letters in drug design & discovery” Researchers identified promising inhibitors for the BRD4 protein, including finasteride and amentoflavone.
9 citations
,
October 2013 in “PLOS ONE” Dutasteride works better than finasteride for preventing and treating prostate cancer.
May 2026 in “AAPS PharmSciTech” PEGylated flavonoid Aspasomes improve brain protection and memory in stress-related disorders.
May 2021 in “Letters in Applied NanoBioScience” Pranlukast and mirabegron may work as new diabetes drugs.
April 2023 in “IntechOpen eBooks” Drug repurposing speeds up drug development, saves money, and has led to about a third of new drug approvals.
16 citations
,
October 2017 in “Journal of steroid biochemistry and molecular biology/The Journal of steroid biochemistry and molecular biology” Dutasteride may protect the brain in early Parkinson's disease.
October 2015 in “Elsevier eBooks” Pramipexole can cause side effects like dizziness, sleepiness, hallucinations, and low blood pressure, and it's important to educate patients and keep doses low.
1 citations
,
January 2024 in “Journal of molecular structure” The new finasteride delivery system using chitosan-based nanoniosomes shows promise for prostate cancer prevention.
December 2025 in “Molecular Pain” Targeting the MC-5-HT-HTR2A axis may help treat chronic itching.
November 2023 in “Magna Scientia Advanced Research and Reviews” Trazodone might help reverse post finasteride syndrome.
1 citations
,
October 2013 in “Urology” More men are using medication for benign prostatic hyperplasia, influenced by marketing and FDA approvals.
1 citations
,
June 2026 in “International Journal of Medical Sciences” Melatonin, known for its antioxidant and anti-inflammatory properties, faces challenges in clinical use due to poor solubility and low bioavailability. This review explores advanced nanotechnology-based delivery systems designed to overcome these barriers, enhancing melatonin's therapeutic potential for diseases like Alzheimer's, Parkinson's, and various cancers. It highlights the design and formulation of melatonin nanocarriers, emphasizing their ability to bypass physiological barriers and improve drug distribution. The review also discusses the relationship between administration routes and therapeutic outcomes, while addressing challenges in clinical translation, such as manufacturing and regulatory issues, aiming to guide future development of melatonin-based therapies.
1 citations
,
September 2007 in “Neuromuscular disorders” The treatment with valproate, acetylcarnitine, folic acid, and vitamin B12 may improve muscle strength in children with SMA without significant side effects.
DiluCap improves how quickly minoxidil and finasteride dissolve and controls the release of melatonin and naltrexone.
7 citations
,
June 2010 in “Bioorganic & medicinal chemistry letters” Two new compounds were found to effectively reduce hair growth in mice.
December 2024 in “IntechOpen eBooks” Drug repurposing speeds up development, cuts costs, and uses known safe drugs, but faces challenges like regulations and patents.
April 2013 in “The FASEB Journal” Dutasteride showed some prevention of prostate issues but also had limitations, especially with high-grade tumors.
105 citations
,
April 2014 in “Trends in Pharmacological Sciences” Targeting the Smoothened receptor shows promise for treating certain cancers.
2 citations
,
December 2021 in “Korean Journal of Clinical Pharmacy”
October 2025 in “International Journal of Innovative Research in Technology” Personalized supplements are important for women's health, but hormone therapy can increase cancer and heart risks.